Wells Fargo Upgrades Viridian Therapeutic (VRDN) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/22/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
- Emirates refusing to take delivery of first 10 Boeing 777X jets
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- Crude Inventory Rose 2 Million Barrels Last Week - EIA
- Wall St ends higher on chip stocks recovery; earnings in focus
- Palo Alto Networks to acquire Embrace to expand observability tools
Viridian Therapeutic (VRDN) PT Raised to $43 at Wedbush
June 29, 2026 12:25 PM EDTWedbush analyst Laura Chico raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $43.00 (from $32.00) while maintaining a Outperform rating.
The analyst comments "Remain Outperform rated on VRDN, new $43 target. Most notable on the VRDN investor call, management confirmed the Lumvoa price... More
William Blair on Viridian Therapeutic (VRDN): 'We came away from the call incrementally more confident'
June 29, 2026 12:25 PM EDTWilliam Blair analyst Lachlan Hanbury-Brown reiterated an Outperform rating on Viridian Therapeutic (NASDAQ: VRDN)
The analyst comments "On Monday, June 29, Viridian hosted a call to discuss the approval and commercial launch of Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED).... More
